<DOC>
	<DOCNO>NCT00086359</DOCNO>
	<brief_summary>Pregnant woman infect HIV take anti-HIV medication pregnancy low risk pass HIV infant . This study compare well two different combination anti-HIV medication control HIV pregnancy , whether combination drug effective prevent HIV transmit pregnant woman baby . The two combination abacavir/lamivudine/zidovudine ( ABC/3TC/ZDV ) zidovudine/lamivudine ( ZDV/3TC ) plus lopinavir/ritonavir ( LPV/RTV ) .</brief_summary>
	<brief_title>Comparison Anti-HIV Drug Combinations Prevent Mother-to-Child Transmission HIV</brief_title>
	<detailed_description>Antiretroviral therapy ( ART ) pregnancy dramatically reduce rate perinatal HIV transmission . Many pregnant woman infect HIV may meet criterion treatment set forth Department Health Human Services ' guideline would start therapy pregnant . Pregnant woman prescribe variety treatment regimens ; optimum regimen pregnant woman plan discontinue therapy delivery unknown . An optimum regimen would account need maximum viral suppression , minimal fetal toxicity , preservation future therapeutic option mother . This study compare nucleoside reverse transcriptase inhibitor ( NRTI ) regimen ABC/3TC/ZDV standard protease inhibitor ( PI ) regimen LPV/RTV 3TC/ZDV . This study initially design woman plan take antiretrovirals pregnant meet criterion treatment initiation pregnant . However , pregnant woman take ART 180 day less take ZDV monotherapy total 8 week less prior enter study eligible Version 2.0 study . Women study randomly assign one two group . Women Group A receive one pill ABC/3TC/ZDV twice day . Women Group B receive one pill 3TC/ZDV 4 pill LPV/RTV twice day . Women take assigned medication go labor . Once labor , woman give zidovudine intravenous ( IV ) infusion ; stop take oral zidovudine continue medication . After delivery , infant give zidovudine six week . Women study visit every 2 week first 8 week treatment , every 4 week Week 28 . Depending woman pregnancy enrolls study , also study visit Weeks 20 , 28 , 34 pregnancy . At visit , woman medical interview , physical exam , obstetrical exam ; blood urine collection occur visit . Mothers undergo fetal ultrasound Week 20 . Adherence , health status , behavior assessment occur select visit prior delivery . After delivery , woman stop take study medication continue study visit approximately 6 , 12 , 24 , 36 , 48 , 52 week delivery . Medical history physical exam occur visit mother postpartum . Blood collection occur every postpartum visit ; urine collection occur 12 , 24 , 48 week postpartum ; health status behavior assessment occur visit postpartum . Infants study visit 2 , 16 , 24 week birth . A medical history , physical exam , laboratory test conduct infant study visit . Women also ask enroll infant PACTG 219C , long-term study follow infant born HIV infect mother .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Note : The pharmacokinetics test portion study discontinue Version 2.0 protocol . Inclusion Criteria Mothers : HIV infect Between 12th 30th week pregnancy Intend continue pregnancy Viral load le 55,000 copies/ml within 30 day study entry CD4 count great 350 cells/ml within 30 day study entry Have previously take antiHIV medication ( woman take 8 week few zidovudine still eligible ) OR take antiHIV medication treatment 180 day Intend stop take antiHIV medication pregnancy Willing infant test HIV Parent guardian willing provide inform consent , applicable Have access participate site willing follow duration study Exclusion Criteria Mothers : Chemotherapy active cancer Active opportunistic infection severe medical condition within 14 day study entry Chronic diarrhea within 1 month study entry unresolved acute diarrhea within 7 day study entry Certain abnormal laboratory value Diabetes mellitus pregnant . Participants gestational diabetes exclude . Current alcohol substance abuse , opinion investigator , may interfere study Acute hepatitis within 90 day study entry Major birth defect infant Severe skin disorder ( e.g. , eczema psoriasis ) require systemic treatment Require certain medication Medical condition may , opinion investigator , interfere study Intend breastfeed</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Treatment Naive</keyword>
	<keyword>Perinatal Transmission</keyword>
	<keyword>Mother-to-Child Transmission</keyword>
	<keyword>MTCT</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>